Jade Biosciences, Inc.
Explore Jade Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
JBIO — Monthly Price History
Adjusted close price · Hover to see price & month
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Regeneron Pharmaceuticals, Inc. | $635.45 | 15.1 | $66.78 B | 0.6% | 10.23% | 14.32% | $821.11 / $476.49 | $295.71 |
| 2. | Alnylam Pharmaceuticals, Inc. | $303.05 | 70.37 | $40.62 B | — | 14.33% | 98.29% | $495.55 / $283.1 | $5.96 |
| 3. | Royalty Pharma plc | $55.87 | 38.89 | $32.17 B | 1.71% | 8.21% | 12.67% | $56.07 / $33.37 | $11.22 |
| 4. | Revolution Medicines, Inc. | $149.23 | — | $31.73 B | — | -57.28% | -54.06% | $166.5 / $34 | $8.28 |
| 5. | Roivant Sciences Ltd. | $28.58 | — | $27.48 B | — | -21.06% | -6.85% | $32.79 / $10.71 | $6.28 |
| 6. | Insmed Incorporated | $94.22 | — | $21.48 B | — | -55.4% | -130.11% | $212.75 / $70.57 | $3.45 |
| 7. | Incyte Corporation | $102.38 | 14.53 | $20.8 B | — | 24.67% | 29.2% | $112.29 / $66.74 | $26.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | — | 0 M | 0 M |
| Operating Profit | -34.98 M | -27.4 M | -27.78 M | — | -19.98 M | -14.96 M |
| Net Profit | -31.93 M | -25.18 M | -32.13 M | — | -30.11 M | -16.28 M |
| EPS in Rs | -0.65 | -0.51 | -0.65 | -1.18 | -0.61 | -0.33 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | |
|---|---|---|
| Sales | 0 M | — |
| Operating Profit | -113.54 M | — |
| Net Profit | -127.41 M | — |
| EPS in Rs | -2.58 | — |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | |
|---|---|---|
| Total Assets | 349.78 M | 72.8 M |
| Total Liabilities | 17.26 M | 119.6 M |
| Equity | 332.52 M | -46.8 M |
| Current Assets | 348.82 M | 69.65 M |
| Current Liabilities | 16.54 M | 12 M |
Cash Flow
Last available yearly cash flow history
| 2025 | |
|---|---|
| Operating CF | -94.69 M |
| Investing CF | -247.01 M |
| Financing CF | 360.77 M |
| Free CF | -94.89 M |
| Capex | -0.2 M |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2025 | |
|---|---|
| Revenue Growth % | — |
| Earnings Growth % | — |
| Profit Margin % | — |
| Operating Margin % | — |
| Gross Margin % | — |
| EBITDA Margin % | — |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
| Ex Date | Dividend |
|---|---|
| 2025-04-29 | $2.4 |
Stock Splits
| Date | Split |
|---|---|
| 2025-04-29 | 1:0.0285714 |
Frequently Asked Questions — Jade Biosciences, Inc.
Will Jade Biosciences, Inc. stock hit $20 in 2026?
Jade Biosciences, Inc. (JBIO) is currently trading at $16.94, with a 52-week range of $6.57 to $28.0. Reaching the $20 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.
Wall Street analysts currently have a consensus price target of $28.71 for Jade Biosciences, Inc., with a Strong_buy rating, and the most bullish analysts see the stock reaching as high as $40.0. Whether Jade Biosciences, Inc. can reach $20 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.
Historically, JBIO has delivered a -51.6% CAGR over the past 5 years, which suggests the stock has demonstrated meaningful long-term growth momentum. However, past performance does not guarantee future results, and short-term price movements can be influenced by macroeconomic shifts, interest rate changes, and investor sentiment. Use the JBIO Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.
Is Jade Biosciences, Inc. stock worth buying at $16.94?
Whether Jade Biosciences, Inc. (JBIO) is worth buying at $16.94 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:
Valuation: Valuation data is currently limited — check the full ratios section on StockSifting for the latest P/E, P/B, and EV/EBITDA figures.
Profitability & efficiency: Jade Biosciences, Inc. has a Return on Capital Employed (ROCE) of -34.1%, which reflects modest capital efficiency. Its Return on Equity (ROE) stands at -51.3%.
Financial health: The Debt-to-Equity ratio of 0.26 indicates a conservative balance sheet with more equity than debt, reducing financial risk.
Analyst view: The Wall Street consensus recommendation for JBIO is currently Strong_buy, with a mean price target of $28.71 based on 7 analyst ratings. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.
What is the analyst price target for Jade Biosciences, Inc. (JBIO) in 2026?
As of 2026, Wall Street analysts have set a consensus (mean) price target of $28.71 for Jade Biosciences, Inc. (JBIO), aggregated from 7 analyst ratings. The overall analyst recommendation is Strong_buy.
The price target range spans from $16.0 on the bearish end to $40.0 on the most optimistic projection, with a median target of $24.0. This wide range reflects differing views on Jade Biosciences, Inc.'s growth prospects, competitive positioning, and macroeconomic sensitivity.
It is important to note that analyst price targets are forward-looking estimates based on financial models, earnings projections, and sector assumptions — they are not guarantees. Targets are regularly revised following quarterly earnings results, management guidance updates, or shifts in the broader economic outlook. Stocks can trade significantly above or below analyst targets depending on market conditions. View the full analyst breakdown and track target revisions on the JBIO analysis page on StockSifting.
How much can you earn by reinvesting Jade Biosciences, Inc. dividends?
Dividend reinvestment — commonly known as DRIP (Dividend Reinvestment Plan) — is a powerful wealth-building strategy where instead of receiving your dividend payouts as cash, the dividends are automatically used to purchase additional shares of Jade Biosciences, Inc. (JBIO). Over time, this creates a compounding effect: more shares generate more dividends, which buy even more shares.
The key variables that determine your DRIP returns are: your initial investment amount, the number of years you stay invested, the dividend yield at the time of each reinvestment, and whether Jade Biosciences, Inc. grows or cuts its dividend over time. Market price appreciation of JBIO also plays a significant role — rising share prices increase the value of your accumulated shares.
Use the JBIO DRIP Calculator on StockSifting to enter your investment amount, start date, and contribution frequency — and see a year-by-year breakdown of shares accumulated, dividends earned, and total portfolio value. Past dividend payments are not a guarantee of future payouts. This is not financial advice.